Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2281-2287

  Haier, J ^a   Owzcareck, M ^a   Guller, U ^b   Spagnoli, G C ^b   Burger H ^a   Senninger, N ^a   Kocher, Th ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Kantonsspital Baden   (Switzerland)

Author keywords

Esophagus; Immunotherapy; MAGE A antigens; Prognosis

Indexed keywords

57B MONOCLONAL ANTIBODY; CANCER TESTIS ANTIGEN; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; PARAFFIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; PROPORTIONAL HAZARDS MODELS;

EID: 33745529277     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841, 1999.
2. Adham M, Baulieux J, Mornex F et al: Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer 89: 946-954, 2000.
3. Lehnert T: Multimodal therapy for squamous carcinoma of the oesophagus. Br J Surg 86: 727-739, 1999.
4. Eriguchi M and Fujii G: Oral administration of BCG as a local immunotherapy of gastrointestinal cancer. J Surg Oncol 26: 100-106, 1984.
5. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P and Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337-365, 1994.
6. Boon T, Gajewski TF and Coulie PG: From defined human tumor antigens to effective immunization? Immunol Today 16: 334-336, 1995.
7. De Plaen E, Arden K, Traversari C et al: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40: 360-369, 1994.
8. Brasseur F, Rimoldi D, Lienard D et al: Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63: 375-380, 1995.
9. Inoue H, Mori M, Li J et al: Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 63: 523-526, 1995.
10. Patard JJ, Brasseur F, Gil-Diez S et al: Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 64: 60-64, 1995.
11. Weber J, Salgaller M, Samid D et al: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 54: 1766-1771, 1994.
12. Koketsu S, Watanabe T, Kazama S, Ishihara S, Komuro Y and Nagawa H: What types of colorectal cancer overexpress the MAGE protein? Hepatogastroenterology 51: 1648-1652, 2004.
13. Zhao L, Mou DC, Leng XS, Peng JR, Wang WX, Huang L, Li S and Zhu JY: Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 10: 2034-2038, 2004.
14. Kienstra MA, Neel HB, Strome SE and Roche P: Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 25: 457-463, 2003.
15. Nagashima H, Sadanaga N, Mashino K, Yamashita K, Inoue H, Mori M and Sugimachi K: Expression of MAGE-B genes in esophageal squamous cell carcinoma. Jpn J Cancer Res 92: 167-173, 2001.
16. Lin J, Lin L, Thomas DG, Greenson JK, Giordano TJ, Robinson GS, Barve RA, Weishaar FA, Taylor JM, Orringer MB and Beer DG: Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Clin Cancer Res 10: 5708-5716, 2004.
17. Inoue H, Mori M, Li J, Mimori K, Honda M, Nakashima H, Mafune K, Tanaka Y and Akiyoshi T: Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 63: 523-526, 1995.
18. Toh Y, Yamana H, Shichijo S, Fujita H, Tou U, Sakaguchi M, Kakegawa T and Itoh K: Expression of MAGE-1 gene by esophageal carcinomas. Jpn J Cancer Res 56: 714-717, 1995.
19. Quillien V, Raoul JL, Heresbach D, Collet B, Toujas L and Brasseur F: Expression of MAGE genes in esophageal squamous-cell carcinoma. Anticancer Res 17: 387-391, 1997.
20. Zambon A, Mandruzzato S, Parenti A, Macino B, Dalerba P, Ruol A, Merigliano S, Zaninotto G and Zanovello P: MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer 91: 1882-1888, 2001.
21. Juretic A, Spagnoli GC, Schultz-Thater E and Sarcevic B: Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 4: 104-109, 2003.
22. Schultz-Thater E, Noppen C, Gudat F, Dürmüller U, Zajac P, Kocher T, Heberer M and Spagnoli GC: NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer 83: 204-208, 2000.
23. Kocher Th, Schultz-Thater E, Gudat F, Schaefer Ch, Casorati G, Juretic A, Willimann Th, Harder F, Heberer M and Spagnoli GC: Identification and intracellular location of MAGE-3 gene product. Cancer Res 55: 2236-2239, 1995.
24. Cox D: Regression models and life tables. J R Stat Soc 34: 187-220, 1972.
25. Kocher T, Zheng M, Bolli M et al: Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 100: 702-705, 2002.
26. Dhodapkar MV, Osman K, Teruya-Feldstein J et al: Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 3: 9, 2003.
27. Murer K, Urosevic M, Willers J et al: Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients. Melanoma Res 14: 257-262, 2004.
28. Kavalar R, Sarcevic B, Spagnoli GC et al: Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Arch 439: 127-131, 2001.
29. Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, Ohashi M and Hatakeyama K: Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: implications for immunotherapy. Int J Cancer 118: 123-128, 2006.
30. Zhao L, Mou DC, Leng XS, Peng JR, Wang WX, Huang L, Li S and Zhu JY: Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 10: 2034-2038, 2004.
31. Koketsu S, Watanabe T, Kazama S, Ishihara S, Komuro Y and Nagawa H: What types of colorectal cancer overexpress the MAGE protein? Hepatogastroenterology 51: 1648-1652, 2004.
32. Kienstra MA, Neel HB, Strome SE and Roche P: Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 25: 457-463, 2003.
33. Ottaviani S, Colau D, van der Bruggen P and der Bruggen PV: A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells. Cancer Immunol Immunother 1-6, 2005.
34. Kobayashi T, Lonchay C, Colau D, Demotte N, Boon T and van der Bruggen P: New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells. Tissue Antigens 62: 426-432, 2003.
35. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T and Mori M: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7: 2277-2284, 2001.
36. Bodey B: Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin Biol Ther 2: 577-584, 2002.
37. Yamana H: Immunotherapy for esophageal carcinoma. Nippon Geka Gakkai Zasshi 103: 376-380, 2002.